Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25447317 | 0.89 | ESR2 (0.46) | ESR2NR1H2MAPTHPGDSDDB1 | |
| SCHEMBL20792566 | 0.86 | ESR2 (0.43) | ESR2NR1H2MAPTHPGDSDDB1 | |
| SCHEMBL20792568 | 0.85 | ESR2 (0.42) | ESR2NR1H2MAPTHPGDSDDB1 | |
| SCHEMBL16210543 | 0.83 | MAPT (0.50) | ESR2NR1H2MAPTHPGDSDDB1 | |
| SCHEMBL1016779 | 0.81 | MAPT (0.48) | ESR2NR1H2MAPTHPGDSDDB1 | |
| SCHEMBL1171431 | 0.80 | MAPT (0.43) | ESR2NR1H2MAPTHPGDSDDB1 | |
| SCHEMBL25447282 | 0.80 | MAPT (0.47) | ESR2NR1H2MAPTHPGDSDDB1 | |
| SCHEMBL25447281 | 0.79 | MAPT (0.47) | ESR2NR1H2MAPTHPGDSDDB1 | |
| SCHEMBL25172506 | 0.79 | TMEM97 (0.46) | PRMT5WDR77GPR119 | |
| SCHEMBL30793206 | 0.79 | ESR2 (0.44) | ESR2NR1H2MAPTHPGDSDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672958-B1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-3672958-B1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-11458140-B2 | Annulated glycosidase inhibitors | ASCENEURON SA (CH) | 2022-10-04 | — | — | US | disclosed |
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2020-09-17 | — | — | US | disclosed |
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2020-09-17 | — | — | US | disclosed |
| EP-3672958-A1 | ANNULATED GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019037861-A1 | ANNULATED GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019037861-A1 | ANNULATED GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | GAA, GBA3, ENGASE | ESR2 2527/4885NR1H2 1653/4885MAPT 26/4885 |
| US-11458140-B2 | Annulated glycosidase inhibitors | GAA, GBA3, ENGASE | ESR2 2527/4885NR1H2 1653/4885MAPT 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.